GRAL Stock Recent News

GRAIL's Galleri   Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience  MENLO PARK, Calif. and SECAUCUS, N.J.

Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer screening blood tests.

Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 index in recent trading.

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif. , Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology.

24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season.

Grail's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has significant backing and aims to reduce costs while expanding its market presence and regulatory validation. Despite high cash burn, Grail's strong cash reserves and strategic focus on FDA approval and Medicare reimbursement present substantial upside potential.

MENLO PARK, Calif. , Aug. 30, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 182,223 shares of GRAIL's common stock to 55 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

Data Support Clinical Performance of Galleri   to Detect More Aggressive Prostate Cancers MENLO PARK, Calif. , Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology.

GRAIL Inc. (NASDAQ:GRAL ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Bob Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Conference Call Participants Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Operator Good day, ladies and gentlemen, and welcome to the GRAIL Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.

Cancer test maker Grail said on Tuesday it would reduce existing headcount and planned hires for 2024 by about 30%, as part of its restructuring program.